These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2039213)

  • 1. Susceptibility of anaerobic bacteria to BAY v 3522.
    Nord CE; Rylander M; Norrby SR
    Antimicrob Agents Chemother; 1991 Mar; 35(3):594-9. PubMed ID: 2039213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of the new oral cephalosporin Bay v 3522 against aerobic and anaerobic bacteria.
    Rylander M; Nord CE; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):777-82. PubMed ID: 2261923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies with Bay V 3522, a new oral cephalosporin.
    Thomson KS; Sanders CC; Sanders WE
    Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
    Hodges TL; Eliopoulos GM; Klimm K; Moellering RC
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1849-54. PubMed ID: 2285305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].
    Dubreuil L; Derriennic M; Sedallian A
    Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative activity of 9 beta-lactamines, clindamycin and metronidazole on strictly anaerobic bacteria].
    Derriennic M; Reynaud A; Launay C; Courtieu AL
    Pathol Biol (Paris); 1987 May; 35(5):572-6. PubMed ID: 3302862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):550-1. PubMed ID: 2548866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of 800 anaerobic isolates from patients with dentoalveolar infection to 13 oral antibiotics.
    Kuriyama T; Williams DW; Yanagisawa M; Iwahara K; Shimizu C; Nakagawa K; Yamamoto E; Karasawa T
    Oral Microbiol Immunol; 2007 Aug; 22(4):285-8. PubMed ID: 17600542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of anaerobic bacteria to ALP 201.
    Nord CE; Lindmark A; Persson I
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2137-9. PubMed ID: 2619278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefoxitin and parenterally administered cephalosporins against anaerobic bacteria.
    Sutter VL; Kirby B; Finegold SM
    Rev Infect Dis; 1979; 1(1):218-23. PubMed ID: 318226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
    Doern GV; Tubert TA
    Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.
    Pierard D; De Meyer A; Rosseel P; Van Cauwenbergh M; Struelens MJ; Delmee M; Goossens H; Claeys G; Glupczynski Y; Verbist L; Melin P; Lauwers S
    Acta Clin Belg; 1996; 51(2):70-9. PubMed ID: 8693871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic sensitivity testing of anaerobic bacteria by the breakpoint method.
    Höffler U; Pulverer G
    Chemotherapy; 1984; 30(6):392-7. PubMed ID: 6518836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of anaerobic bacteria to FCE 22101.
    Nord CE; Lindmark A; Person I
    Antimicrob Agents Chemother; 1987 May; 31(5):831-3. PubMed ID: 3038012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1064-7. PubMed ID: 2559846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.